Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis.

ABSTRACT:

Objective

We compared the 52-week effectiveness and safety of tofacitinib (TOF) and abatacept (ABT) in patients with RA in a real-world setting and investigated a role of human leucocyte antigens (HLA)-DRB1 shared epitope (SE) in the effectiveness.

Methods

RA patients starting TOF (n = 187) and ABT (n = 183) were enrolled. Effectiveness was compared after reducing the selection bias to a minimum using the inverse probability of treatment weighting (IPTW) based on propensity scores. The influence of SE alleles on effectiveness was compared within each treatment group. A treatment group comparison was also performed within SE-positive and SE-negative groups.

Results

Herpes zoster and some laboratory abnormalities were more frequent in the TOF group than in

SUBMITTER: Hirose W 

PROVIDER: S-EPMC9667967 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature